

- 5 Naruya Tomita, Toshio Ogihara,  
Ryuichi Morishita Therapeutic  
potential of  
oligonucleotides strategy in  
cardiovascular diseases  
Expert Review of Cardiovascular  
Therapy 2003, September  
VOl1 No3 463-470
- 6 森下 竜一 炎症や免疫を抑制  
する「おとり」医薬 ゲノムか  
らくすりへ 2003年 15-16

H. 知的所有権の出願・登録状況(予  
定を含む)

- 1 特許取得  
なし
- 2 実用新案登録  
なし
- 3 その他  
なし

2 学会発表

- 1 森下 竜一 「遺伝子治療のア  
レルギー性皮膚疾患に対する  
新展開」第33回 日本皮膚ア  
レルギー学会 総会・学術大会  
2003年7月5日 東京
- 2 森下 竜一 「Comparison of the  
ointment containing NF $\kappa$ B  
decoy oligodeoxynucleotides  
with tacrolimus hydrate Rapid  
regression and no tachyphylaxis in  
the treatment of atopic dermatitis  
in NC/Nga atopic mice model」  
The Japan Society of Gene  
Therapy  
2003年7月18日 京都
- 3 森下 竜一 「皮膚関連疾患の  
遺伝子治療 from bench to bed」  
L O皮膚科学研究会夏季プロ  
グラム 2003年8月30日 東京

§ 研究成果の刊行に関する一覧

著者氏名	論文タイトル名	発表雑誌名	巻号	ページ	出版年
Oshima K, Shimamura M, Mizuno S, Tamaï K, Doi K, Morishita R, Toshikazu Nakamura T Kubo T, Kaneda Y	Intrathecal injection of HVJ-E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairment in rats	FASEB J		in press	
Umegaki N, Moritsugu R, Katoh S, Harada K, Nakano H, Tamaï K, Hanada K, Tanaka M	Photodynamic therapy may be useful to debulk cutaneous lymphoma prior to radiotherapy	British J Dermatol		in press	
Umegaki N, Moritsugu R, Katoh S, Harada K, Nakano H, Tamaï K, Hanada K, Tanaka M	Photodynamic therapy may be useful in debulking cutaneous lymphoma prior to radiotherapy	Clinical and Experimental Dermatology	29	42-45	2004
Tamaï K, Hashimoto I, Hanada K, Ikeda S, Imamura S, Ogawa H	Japanese guidelines for diagnosis and treatment of junctional and dystrophic epidermolysis bullosa	Arch Dermatol Res	295	S24-S28	2003
Kaneda Y, Tamaï K	Current status and future prospects of gene therapy technologies toward the treatment of intractable skin diseases.	Arch Dermatol Res	295	63-66	2003
Matsuzaki Y, Tamaï K, Kon A, Sawamura D, Uitto J, Hashimoto M,	Keratinocyte responsive element 3(KRE3) Analysis of a keratinocyte-specific regulatory sequence in the 230-kD bullous pemphigoid antigen(BPAG1) gene promoter.	J Invest Dermatol	120	308-12	2003
玉井 克人	アトピー性皮膚炎の遺伝子治療	最新医学 (最新医学社)	16	157-163	2003
玉井 克人 森下 竜一 中邨 広重 金田 安史 花田 勝美	アトピー性皮膚炎に対する核酸医薬導入による新しい治療法	アレルギー・免疫 (医薬ジャーナル社)	10(3)	89-96	2003

Midorikawa K, Ouhara K, Komatsuzawa H, Kawai T, Yamada S, Fujiwara T, Yamzaki K, Sayama K, Taubman M A, Kurihara H, <u>Hashimoto K</u> , Sugai M	Staphylococcus aureus Susceptibility to Innate Antimicrobial Peptides, $\beta$ - Defensins and CAP18, Expressed by Human Keratinocytes	Infection and Immunity	71 (7)	3730-3739	2003
Shirakata Y, Tamai K, Nakaoka H, Tokumaru S, Sayama K, Murakami S, <u>Hashimoto K</u>	Severe Palmo-Plantar Hyperkeratosis in Koebner Epidermolysis Bullosa Simplex	The Journal of Dermatology	30	135-140	2003
<u>Hashimoto K</u> , Yasukawa M, Tohyama M	Human herpesvirus 6 and drug allergy	Drug allergy		255-260	2003
Yanai F, Ishii E, Kojima K, Hasegawa A, Azuma T, Hirose S, Suga N, Mitsudome A, Zaito M, Ishida Y, Shirakata Y, Sayama K, <u>Hashimoto K</u> , Yasukawa M	Essential Roles of Perforin in Antigen-Specific Cytotoxicity Mediated by Human CD4 <sup>+</sup> T Lymphocytes Analysis Using the Combination of Hereditary Perforin-Deficient Effector Cells and Fas- Deficient Target Cells	The Journal of Immunology	170	2205-2213	2003
Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, <u>Hashimoto K</u>	So-called biological dressing effects of cultured epidermal sheets are mediated by the production of EGF family, TGF- $\beta$ and VEGF	Journal of Dermatological Science	32	209-215	2003
Yamasaki K, Hanakawa Y, Tokumaru S, Shirakata Y, Sayama K, Hanada T, Yoshimura A, <u>Hashimoto K</u>	Suppressor of Cytokine Signaling 1/JAB and Suppressor of Cytokine Signaling 3/Cytokine-Inducible SH2 Containing Protein 3 Negatively Regulate the Signal Transducers and Activators of Transcription Signaling Pathway in Normal	The Journal of Investigative Dermatology	120	571-580	2003

Wada T, Shirakata Y, Takahashi H, Murakami S, Iizuka H, Suzuki H, <u>Hashimoto K</u>	A Japanese case of segmental Darier's disease caused by mosaicism for the ATP2A2 mutation	British Journal of Dermatology	149	185-188	2003
Nakamura Y, Fukami K, Yu H, Takenaka K, Kataoka Y, Shirakata Y, Nishikawa S, <u>Hashimoto K</u> , Yoshida N, Takenawa T	Phospholipase C $\delta_1$ is required for skin stem cell lineage commitment	The EMBO Journal	22 (12)	2981-2991	2003
Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, Hanakawa Y, Detmar M, <u>Hashimoto K</u>	Nuclear Translocation of Phosphorylated STAT3 Is Essential for Vascular Endothelial Growth Factor-induced Human Dermal Microvascular Endothelial Cell Migration and Tube Formation	The Journal of Biological Chemistry	278 (41)	40026-40031	2003
Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze M, <u>Hashimoto K</u> , Raab G, Nanba D, Higashiyama S, Hori M, Klagsbrun M, Mekada E	Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function	Proceedings of the National Academy of Sciences	100 (6)	3221-3226	2003
Yamasaki K, Torii N, Hanakawa Y, Shirakata Y, Sayama K, Takayanagi A, Ohtsubo M, Gamou S, Shimizu N, Fuji M, Miyazono K, <u>Hashimoto K</u>	Keratinocyte Growth Inhibition by High-Dose Epidermal Growth Factor Is Medicated by Transforming Growth Factor $\beta$ Autoinduction A Negative Feedback Mechanism for Keratinocyte Growth	The Journal of Investigative Dermatology	120	1030-1037	2003

<u>Kaneda Y,</u> Tamai K	Current status and future prospects of gene therapy technologies toward the treatment of intractable skin diseases	Arch Dermatol Res	295	S63-S66	2003
Ogushi I, Imuro Y, Seki E, Son G, Hirano T, Hada T, Tsutsui H, Nakanishi K, Morishita R, <u>Kaneda Y,</u> Fujimoto J	Nuclear Factor $\kappa$ B Decoy Oligodeoxynucleotides Prevent Endotoxin-Induced Fatal Liver Failure in a Murine Model	Hepatology	38	335-344	2003
Wu M-H, Yokozeki H, Yamamoto T, Satoh T, <u>Kaneda Y,</u> Katayama I, Nishioka K	Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma	Gene Therapy	11	170-180	2004
Yamazaki S, Iwamoto R, Saeki K, Asakura M, Takashima S, Yamazaki A, Kimura R, Mizushima H, Higashiyama S, Endoh M, <u>Kaneda Y,</u> Takagi S, Itami S, Takeda N, Yamada G, Mekada E	Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities	The Journal of Cell Biology	163	469-475	2003
Yamasaki K, Asai T, Shimizu M, Aoki M, Hayashi N, Sakonjo H, Makino H, Kaneda Y, Ogihara T, <u>Morishita R</u>	Inhibition of NF $\kappa$ B activation using cis-element 'decoy' of NF $\kappa$ B binding site reduces neointimal formation in porcine balloon-injured coronary artery model	Gene Therapy	10	356-364	2003
<u>Morishita R,</u> Kaneda Y, Ogihara T	Therapeutic Potential of Oligonucleotide-Based Therapy in Cardiovascular Disease	Current Opinion	17	383-389	2003

Azuma T, Tomita N, Kaneda Y, Ogihara T, Katsuoka Y, <u>Morishita R</u>	Transfection of NFκB-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts	Gene Therapy	10 (5)	415-425	2003
Tomita N, Ogihara T, <u>Morishita R</u>	Therapeutic potential of oligonucleotides strategy in cardiovascular diseases	Expert Review of Cardiovascular Therapy	1 (3)	463-470	2003

20030664

以降は雑誌/図書等に掲載された論文となりますので、  
「研究成果の刊行に関する一覧表」をご参照ください。